PTH and osteosarcoma: In addition, the U.S. FDA issued a mandatory black-box warning that “teriparatide should not be prescribed for patients with an increased baseline risk for osteosarcoma.” However, only two possible osteosarcoma cases have been observed in half a million patients administered PTH [67], indicating that the risk may be negligible in humans.